Polyprenols in the treating inflammatory processes and liver fibrosis
40 patients with non-alcoholic fatty liver disease participated in the study. All of them were treated with ursodeoxycholic acid, with 19 of them additionally received polyprenols within 3 months. Comparison of results of both groups made it possible to conclude that polyprenols have a high hepatoprotective effect in the treatment of patients with chronic liver injury. In addition, they have a positive influence on the immune status, especially on the cellular component of the immune system.
Polyprenols are a plant analogue of the endogenous transport lipid of dolichol that provides reactions of glycosylation in the dolichol phosphate cycle during the synthesis of glycoproteins. The pharmacological action of polyprenols is based on the substitutive effect in cases of deficit of dolichol and insufficiency of the dolichol phosphate cycle in cases of chronic inflammatory and degenerative diseases of the liver. Effects of polyprenols on the membrane-active properties, participation in the repair of damaged cell membranes, biosynthesis of cholesterol, transformation of membrane-bound enzymes were identified in the experimental data. In addition, polyprenols probably are involved in the transportation and redistribution of phospholipids and ubiquinone. In this regard, it is important to study the effects of polyprenols on the course of inflammatory processes in the liver, leading to fibrosis and cirrhosis.
The study included 40 patients with non-alcoholic fatty liver disease. The duration of observation and treatment was 3 months. Dynamics of clinical manifestations, biochemical blood test indicators were assessed in the study: total protein, albumins, bilirubin and its fractions, the activity of liver enzymes (AST, A/1T, ALP, GGT), cholesterol indicators, glucose, prothrombin ratio. Ultrasonic indicators of the liver status were controlled. In the course of the study, the patients were randomized into 2 groups. The first group of patients (n=19) received ursodeoxycholic acid at the dose of 15 mg/kg/day and 40 mg of polyprenols orally at the dose of 3 drops 3 times a day. The control group (n=21) received ursodeoxycholic acid at a dose of 15 mg/kg/day and placebo.
Most patients had positive dynamics of clinical indicators, 72% in the main group and 64% in the control group. The level of ALT and AST in the main group reduced from 146.3 to 37.1 and from 107.7 to 14.2, respectively. Analysis of dynamics of lipid spectrum indicators showed a more intense dynamics in the group of patients taking poliprenol compared to placebo. Reduction of the content of bilirubin was observed in both groups: in the first group – by 31.2%, in the control group – by 18.7%. Signs of liver fibrosis were less pronounced in patients taking ursodeoxycholic acid and polyprenols, which is confirmed by the reduction in the fibrosis index (FibroTest and indirect ultrasonic elastometry) in the group of poliprenol. An increase of active T-lymphocytes and the index of T-helpers/T-suppressors was also observed in the study group. The indicators of CD3+CD4+CD8-, CD3+CD4+CD8-, CD4+CD8+CD3- single, double positive also have a higher prognostic value in the group of patients taking polyprenols. All the given indices evidence the positive effect on the immune status, especially on the cellular component of the immune system.
The text of the study is provided by courtesy of Solagran.